Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity
PROTEOMICS – Clinical Applications · 2025
DOI: 10.1002/prca.70019 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2025. Verfasst von Varshini Babu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Tricuspid Valve Insufficiency, Proteomics. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Purpose
Pulmonary hypertension (PH) is a chronic complication of sickle cell disease (SCD) with limited known biomarkers, beyond increases in plasma brain natriuretic peptide levels. Experimental Design We conducted a proof‐of‐concept study to identify serum protein biomarkers that were differentially expressed in SCD patients with elevated tricuspid regurgitation velocity (TRV—a noninvasive marker of PH).
Results
We found 41 out of 92 target proteins that were significantly different between the nonelevated (TRV ≤ 2.6 m/s; N = 35) and highly elevated TRV group (TRV ≥ 2.9 m/s; N = 35, p < 0.05). Six of them passed a Bonferroni correction ( p value < 0.0005), including T‐cell surface glycoprotein, lymphotactin, SLAM family member 7, galectin‐9, TNF‐related apoptosis‐inducing ligand receptor 2, and tumor necrosis factor receptor superfamily member 11A. We observed up to a 1.2‐fold increase in the high TRV group for these six proteins. These six proteins had a strong positive correlation with serum NT‐proBNP levels (a positive control marker elevated in PH [ r ≥ 0.44]). Additionally, these markers correlated with other clinical parameters of PH in SCD.
Conclusion
Circulatory protein markers of the immune response are increased in SCD patients with elevated TRV as compared to those without elevated TRV. Summary This study demonstrates that the circulatory protein markers of the immune response are increased in SCD patients with elevated TRV compared to those without elevated TRV. These biomarkers may be important tools for risk‐stratifying patients with SCD or targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
- Imperial College London, London, UK.
ORCID-Profile: Varshini Babu
Förderung
- NHLBI NIH HHS
Zitieren
APA
Babu, V., Little, J. A., Morris, C. R., Machado, R., Gibbs, S., Kato, G. J., Gordeuk, V. R., Gladwin, M. T., Zhang, Y., & Nouraie, S. M. (2025). Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70019
Vancouver
Babu V, Little JA, Morris CR, Machado R, Gibbs S, Kato GJ, et al. Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity. PROTEOMICS – Clinical Applications. 2025. doi:10.1002/prca.70019
BibTeX
@article{Babu2025,
author = {Babu, Varshini and Little, Jane A and Morris, Claudia R and Machado, Roberto and Gibbs, Simon and Kato, Gregory J and Gordeuk, Victor R and Gladwin, Mark T and Zhang, Yingze and Nouraie, Seyed Mehdi},
title = {Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity},
journal = {PROTEOMICS – Clinical Applications},
year = {2025},
doi = {10.1002/prca.70019}
}
EUVIMED